To date no xenotransplantation trials have been entirely successful due to obstacles arising from the response of the recipient’s immune system—generally more extreme than in allotransplantations, ultimately results in rejection of the xenograft, and in some cases result in the death of the recipient—including hyperacute rejection, acute vascular rejection, cellular rejection and chronic rejection. An early major breakthrough was the 1,3 galactosyl transferase gene knockout.